Incyte (INCY) Stock Forecast & Price Target

$98.56 +0.79 (+0.81%)

Closing price 05/8/2026 04:00 PM Eastern

Extended Trading

$98.50 -0.06 (-0.06%)

As of 05/8/2026 07:58 PM Eastern

Compare

Incyte - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Hold

Based on 21 Analyst Ratings

Sell
1

Hold
10

Buy
10

Based on 21 Wall Street analysts who have issued ratings for Incyte in the last 12 months, the stock has a consensus rating of "Hold." Out of the 21 analysts, 1 has given a sell rating, 10 have given a hold rating, and 10 have given a buy rating for INCY.

Consensus Price Target

$104.26
5.79% Upside

According to the 21 analysts' twelve-month price targets for Incyte, the average price target is $104.26. The highest price target for INCY is $135.00, while the lowest price target for INCY is $60.00. The average price target represents a forecasted upside of 5.79% from the current price of $98.56.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for INCY and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Incyte and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

INCY Analyst Ratings Over Time

Type	Current Forecast 5/9/25 to 5/9/26	1 Month Ago 4/9/25 to 4/9/26	3 Months Ago 2/8/25 to 2/8/26	1 Year Ago 5/9/24 to 5/9/25
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	10 Buy rating(s)	10 Buy rating(s)	9 Buy rating(s)	4 Buy rating(s)
Hold	10 Hold rating(s)	10 Hold rating(s)	12 Hold rating(s)	13 Hold rating(s)
Sell	1 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)
Consensus Price Target	$104.26	$104.89	$103.29	$73.53
Forecasted Upside	5.79% Upside	8.18% Upside	-4.70% Downside	24.68% Upside
Consensus Rating	Hold	Hold	Hold	Hold

INCY Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

INCY Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Incyte Stock vs. The Competition

Type	Incyte	Medical Companies	S&P 500
Consensus Rating Score	2.43	2.30	2.52
Consensus Rating	Hold	Hold	Moderate Buy
Predicted Upside	5.06% Upside	848.34% Upside	15.29% Upside
News Sentiment Rating	Positive News See Recent INCY News	Neutral News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
5/4/2026	HC Wainwright 3 of 5 stars	Mitchell S. Not Rated	Reiterated Rating	Buy	$135.00	+39.30%
4/29/2026	Oppenheimer 3 of 5 stars	Jay Olson 5 of 5 stars	Boost Target	Market Perform	$84.00 ➝ $90.00	-7.92%
4/29/2026	Stifel Nicolaus 4 of 5 stars	Stephen Willey 5 of 5 stars	Boost Target	Buy	$120.00 ➝ $123.00	+25.84%
4/1/2026	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Hold (C+) ➝ Buy (B-)
3/25/2026	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Ashwani Verma Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Neutral	$104.00 ➝ $94.00	+1.82%
3/24/2026	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Overweight
3/16/2026	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Faisal Khurshid Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade	Buy ➝ Hold	$120.00 ➝ $94.00	+1.58%
2/11/2026	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Vikram Purohit Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target		$102.00	+3.42%
2/11/2026	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Brian Abrahams Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Sector Perform	$95.00 ➝ $92.00	-6.69%
2/11/2026	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Derek Archila Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Equal Weight	$107.00 ➝ $101.00	+2.60%
Get the Latest News and Ratings for INCY and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Incyte and its competitors with MarketBeat's FREE daily newsletter.
2/6/2026	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Allison Bratzel Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$102.00 ➝ $110.00	+7.05%
1/13/2026	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Buy
1/8/2026	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Neutral	$90.00	-18.60%
12/24/2025	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Srikripa Devarakonda Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target		$103.00	+2.07%
12/8/2025	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Salim Syed Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target	Neutral ➝ Outperform	$90.00 ➝ $121.00	+18.03%
11/10/2025	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Strong-Buy ➝ Hold
11/3/2025	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Michael Schmidt Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$125.00	+33.72%
10/9/2025	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jessica Fye Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Neutral	$73.00 ➝ $89.00	+4.24%
9/4/2025	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Tazeen Ahmad Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$90.00 ➝ $104.00	+21.54%
7/30/2025	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Lebowitz Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$88.00 ➝ $103.00	+31.96%
7/30/2025	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Evan Seigerman Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Underperform	$52.00 ➝ $60.00	-23.13%
3/18/2025	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Y Katherine Xu Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
2/11/2025	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reni Benjamin Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Market Perform
1/10/2025	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Eric Schmidt Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Neutral
10/1/2024	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Andy Chen Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Outperform	$84.00	+27.08%
8/1/2024	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target	Hold	$55.00 ➝ $60.00	-6.93%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 01:30 AM ET.

INCY Forecast - Frequently Asked Questions

According to the research reports of 21 Wall Street equities research analysts, the average twelve-month stock price forecast for Incyte is $104.26, with a high forecast of $135.00 and a low forecast of $60.00.

21 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Incyte in the last year. There is currently 1 sell rating, 10 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" INCY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in INCY, but not buy additional shares or sell existing shares.

According to analysts, Incyte's stock has a predicted upside of 5.79% based on their 12-month stock forecasts.

Over the previous 90 days, Incyte's stock had 2 upgrades and 2 downgrades by analysts.

Incyte has been rated by research analysts at Barclays, HC Wainwright, Jefferies Financial Group, Morgan Stanley, Oppenheimer, Royal Bank Of Canada, Stifel Nicolaus, UBS Group, Weiss Ratings, and Wells Fargo & Company in the past 90 days.

Analysts like Incyte more than other "medical" companies. The consensus rating score for Incyte is 2.43 while the average consensus rating score for "medical" companies is 2.30. Learn more on how INCY compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Incyte Recommendations

This page (NASDAQ:INCY) was last updated on 5/9/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Incyte (INCY) Stock Forecast & Price Target

Incyte - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

INCY Analyst Ratings Over Time

INCY Analyst Recommendations By Month

INCY Price Targets by Month

Incyte Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

INCY Forecast - Frequently Asked Questions

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Incyte Recommendations

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Incyte (INCY) Stock Forecast & Price Target

Incyte - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

INCY Analyst Ratings Over Time

INCY Analyst Recommendations By Month

INCY Price Targets by Month

Incyte Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

INCY Forecast - Frequently Asked Questions

What is Incyte's forecast for 2026?

Should I buy or sell Incyte stock right now?

Does Incyte's stock price have much upside?

Has Incyte been upgraded or downgraded by Wall Street analysts recently?

What analysts cover Incyte?

Do Wall Street analysts like Incyte more than its competitors?

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Incyte Recommendations

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools